Nonselective inhibition of the IR causes hyperglycemia, and inhibition of the insulin-like growth factor-1 receptor (IGF1R), which also contributes to glucose metabolism, commonly induces hyperglycemia in cancer clinical trials (2, 40, 41). Here, IGF1R is linked to Hyperglycemia.